An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Given the role of IL-17 in the development of entheseal-driven pathology, a therapeutic
strategy aimed at blocking IL-17 would be a logical option for the treatment of enthesitis in
psoriatic arthritis patients. This study will be the first randomized trial of a biologic
therapy in participants with psoriatic arthritis, using imaging test.